Author

Paloma Maín

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Andrea Zapater-Moros· 2 shared Angelo Gámez-Pozo· 2 shared Enrique EspinosaiD· 2 shared Guillermo Prado-Vázquez· 2 shared Hilario NavarroiD· 2 shared Jorge M Arevalillo· 2 shared Juan Ángel Fresno VaraiD· 2 shared Lucía Trilla-Fuertes· 2 shared

Activity by Year

2017-2018 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andrea Zapater-Moros

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMay 21, 2018

Novel Molecular Classification of Muscle-Invasive Bladder Cancer Opens New Treatment Opportunities

Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Guillermo Prado-Vázquez…·Juan Ángel Fresno Vara

This paper uses computational analyses on TCGA data to classify muscle-invasive bladder cancer into Luminal, Basal, and immune-high groups, suggesting targeted therapies for each.

DOI 10.1101/327114

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintOct 27, 2017

Probabilistic Graphical Models Relate Immune Status With Response To Neoadjuvant Chemo-Therapy In Breast Cancer

Andrea Zapater-Moros, Angelo Gámez-Pozo, Guillermo Prado-Vázquez…·Juan Ángel Fresno Vara

The paper uses probabilistic graphical models on gene expression data from breast cancer patients to show that immune-related functions and markers are more active in tumors that respond completely to neoadjuvant chemotherapy.

DOI 10.1101/210112

humanbulk RNA-seq

𝕏 PostBluesky